stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Net income
CRISPR Therapeutics AG's net income for fiscal 2025 was −$581.6M, compared with −$366.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$456.1M. Over the past ten years it has ranged from −$650.2M (fiscal 2022) to $377.7M (fiscal 2021); the current reading is higher than 18% of that period. CRISPR Therapeutics AG ranks 583rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$581.6M | — |
| FY2024 | −$366.3M | — |
| FY2023 | −$153.6M | — |
| FY2022 | −$650.2M | — |
| FY2021 | $377.7M | — |
| FY2020 | −$348.9M | — |
| FY2019 | $66.9M | — |
| FY2018 | −$165.0M | — |
| FY2017 | −$68.4M | — |
| FY2016 | −$23.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$111.4M | — |
| Jun 2026 | −$91.2M | — |
| Mar 2026 | −$122.9M | — |
| Dec 2025 | −$130.6M | — |
| 41 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $1.0B |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$56.2M |
| TVTX Travere Therapeutics, Inc. compare | −$121.5M |
| MANE Veradermics Incorporated compare | −$136.4M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| ERAS Erasca, Inc. compare | −$287.2M |
| DFTX Definium Therapeutics, Inc. compare | −$353.8M |
| COGT Cogent Biosciences, Inc. compare | −$377.2M |
| CRSP CRISPR Therapeutics AG | −$456.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on CRSP
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement